Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Assets (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Current Assets readings, the most recent being $594.2 million for Q1 2026.

  • On a quarterly basis, Current Assets rose 66.95% to $594.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $594.2 million, a 66.95% increase, with the full-year FY2025 number at $527.2 million, up 58.88% from a year prior.
  • Current Assets hit $594.2 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $527.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $594.2 million in Q1 2026 to a low of $179.9 million in Q2 2022.
  • Median Current Assets over the past 5 years was $276.3 million (2023), compared with a mean of $321.3 million.
  • Biggest five-year swings in Current Assets: dropped 27.87% in 2022 and later surged 66.95% in 2026.
  • Kiniksa Pharmaceuticals International's Current Assets stood at $243.1 million in 2022, then rose by 13.67% to $276.3 million in 2023, then grew by 20.09% to $331.8 million in 2024, then surged by 58.88% to $527.2 million in 2025, then rose by 12.71% to $594.2 million in 2026.
  • The last three reported values for Current Assets were $594.2 million (Q1 2026), $527.2 million (Q4 2025), and $475.5 million (Q3 2025) per Business Quant data.